Use of autologous bone marrow stem cell implantation for osteonecrosis of the knee in sickle cell disease: a preliminary report

Abstract

BackgroundThe purpose of our study was to evaluate safety, feasibility and clinical results of bone marrow mononuclear cell (BMC) implantation for early-stage osteonecrosis of the knee (OK) secondary to sickle cell disease.MethodsThirty-three SCD patients (45 knees) with OK treated with BMC implantation in the osteonecrotic lesion were clinically and functionally evaluated through the American Knee Society Clinical Score (KSS), Knee Functional Score (KFS) and Numeric Rating Scale (NRS) pain score. MRI and radiographic examinations of the knee were assessed during a period of five years after intervention.ResultsNo complications or serious adverse event were associated with BMC implantation. From preoperative assessment to the latest follow-up, there was a significant (p < 0.001) improvement of clinical KSS (64.3 ± 9.7, range: 45–80 and 2.2 ± 4.1, range: 84–100, respectively), KFS (44.5 ± 8.0, range: 30–55 and 91.6 ± 5.8, range: 80–100, respectively) and reduction of NRS pain score (6.7 ± 1.2, range: 4–9 and 3.4 ± 1.0, range: 2–5, respectively). In total, 87% of patients (29/33) consistently experienced improvements in joint function and activity level as compared to preoperative score. No patient had additional surgery following BMC implantation. Radiographic assessment showed joint preservation and no progression to subchondral collapse at most recent follow-up.ConclusionsThe technique of BMC implantation is a promising, relatively simple and safe procedure for OK in SCD patients. Larger and long-term controlled trials are needed to support its clinical effectiveness.Trial registrationClinicalTrials.gov NCT02448121. Retrospectively registered 19 May 2015.

Therapy with bone marrow mesenchymal stem cells in bone regeneration in children with osteonecrosis secondary to sickle cell disease

“…In our study, further corroborating findings from important literature sources (Daltro et al, 2008;Hernigou et al, 2008;Daltro et al, 2015;Daltro et al, 2018b), nearly 70% of cases stabilized, meaning there was no disease progression, which is very important for these patients, especially considering their young age. Thus, we were able to postpone the need for prosthesis for approximately 10 years (Hernigou and Beaujean, 2002).…”

Comparative Clinical Trial Between Conventional Treatment and Treatment with Rich Plasma Implants in Platelets (PRP) in Patients with Pseudarthrosis in the Tibia

“…The [32,34,48]. In mode general, you factor in growth are mediators biological natural what act synergistically at regulation gives division, chemotaxis, differentiation, and metabolisms cell phones involved at the process in repair tissue [22,49].…”

Comparative Analysis of Knee Joint Replacement and Stem Cells Therapy Treatment for Knee Osteoarthritis Using Statistical Techniques

“…It further explains that approximately 20% of Knee joint replacement patients experience loss of function in the next 12 months of procedure. The report [6] elaborates the significance of implementing ADSC therapy techniques for SCD (Sickle cell disease) patients to overcome knee OA [6]. It was seen that procedure was safe and feasible and moreover the results were satisfactory.…”